

PREGNANT WOMEN WITH CORONAVIRUS

Khafizova Dilnoza

Mankind has faced an unprecedented level of war on a global scale, in which our common enemy is the new coronavirus. At the same time, our hospitals have become a battlefield, and our medical staff – soldiers [5].

The main condition for the victory of mankind in this battle is to provide medical personnel with the necessary resources and to create technical knowledge and tools that will allow them to share experiences [2]. To do this, we need to be confident that the virus on the battlefield of the hospital is not us, but we will defeat the virus. According to the World Health Organization (WHO), viral diseases continue to emerge and are a serious problem for public health. In the last 20 years, several viral epidemics have been recorded, for example, coronavirus (SARS-CoV) with Acute Respiratory Syndrome in 2002-2003 years, as well as H1N1 grippi in 2009. In addition, in 2012 Year in Saudi Arabia, the coronavirus of Respiratory Syndrome (MERS-CoV) was also detected [1, 4].

For the first time, the respiratory coronavirus (COVID -19), which has spread in the city of Wuhan, the largest capital of the province of Hubei in China, and now manifests itself as a pandemic in countries around the world, was reported to the WHO Chinese office on December 31, 2019. Since the causative agent of the disease was not clear, these cases were described as " pneumonia with an unknown etiology." A program for Disease Control and Prevention was developed in the Chinese Center and local hospitals, and as a result of inspections it was found that the etiology of this disease is a virus belonging to the coronavirus family. On February 11, 2020, who General Director Tedros A.G. announced the appearance of this new coronavirus is "coronavirus-2019" (COVID-19). Since this virus is very contagious, it soon became a pandemic in global quantities [2, 6].

According to the American doctor Obstetricians and Gynecologists, until now, the indicator of pregnant women among those infected with the COVID -19 virus is not high. However, the gripp noted that there is a high risk of infection from the COVID -19 virus, such as upper respiratory infections. It is known that during pregnancy, the female body undergoes various changes, which in its place causes a decrease in the immune system [1, 5]. This in turn leads to the fact that various infections badly affect both the pregnant woman and the fetus. In pregnancy, respiratory viral infections, such as gripp, cause premature births and the birth of low-weight babies. In addition, high fever, manifested as a result of viral infections, leads to the development of congenital defects in the fetus.

Despite the fact that pregnant women are more prone to a viral disease, it has already been known that changes in the immune system during pregnancy can be associated with more serious symptoms [3, 4]. By COVID -19, serious symptoms such as pneumonia, respiratory failure are widely described in the elderly, followed by immunosuppression and in patients with long-term diseases such as diabetes, cancer and chronic lung disease. Similar symptoms can also occur in pregnant women due to the appearance of several changes in the immune system, which means that it is necessary to immediately identify and treat the risk group.

During the pandemic of 2002–2003, 12 pregnant women became infected with the SARS-CoV virus. 7 pregnancies were in the first trimester and 4 (57%) fetal deaths. In the II-III trimester, 2 women had delayed fetal development (40%) and 5 had premature births (80%). Three women died during pregnancy. When 11 pregnant women were tested for MERS-CoV, 91% had adverse events, 6 had a neonatal condition, and 3 had infant deaths (27%) [2, 6]. The development of respiratory failure during pregnancy has led to premature termination of pregnancy. It is noteworthy that the 2019-CoV virus also causes such high pathogenic complications as the SARS-CoV and MERS-CoV viruses, indicating a high risk that this infection will lead to drift complications in pregnancy. Coronavirus infection can be caused by both a pregnant woman and a fetus [1, 2].

Clinical manifestations of viral infections occur individually for each pregnant woman. According to data from Australia, it found a significant increase in the incidence of diseases in later stages of pregnancy. Other types of coronavirus infections (SARS, MERS) are considered to be a high-risk condition for pregnant women, especially in the last trimester of pregnancy, this risk increases. Recently in one study it was stated that the cause of premature termination of pregnancy due to the medical condition of a pregnant woman.

Effects on pregnancy

Currently, there is no evidence of an increased risk of pregnancy or premature termination due to COVID-19. However, in an article published on March 26, to date, coronavirus antibodies have been detected in the blood of 3 infants born to a pregnant woman infected with COVID-19, but the virus itself has not been detected in the umbilical cord blood. According to WHO, 3 April 2020 year, however, in the RF, it was announced the birth of the first baby infected with COVID -19. There is also currently only one case in which a woman with severe COVID -19 disease was sent to the hospital for 34 weeks, was born in an emergency for an unborn child and was admitted to the intensive care unit with an acute respiratory syndrome requiring urgent medical care [6].

There is currently no evidence of a teratogenic virus. But according to the latest data, there is a possibility of vertical transmission of the virus, but the ratio of pregnancy and the value of the newborn still need to be determined.

Clinical course and diagnosis during pregnancy

Any viral infection during pregnancy is an additional risk. Gripp, herpes, and sitomegalovirus and other viral infections produce many complications especially in the early stages of pregnancy. Organogenesis, during the period of development of organs and tissues, a viral infection can quickly affect the embryo, causing various complications: early miscarriage, the development of the fetus, premature birth or premature withdrawal of papaya water and similar complications. These complications can also be observed in cases of damage to the coronavirus, but we do not know for sure, but we know that there is a risk of serious consequences.

So far, it has not been proven that the virus passes through the fetoplacental barrier in a pregnant woman infected with the coronavirus, as a pregnant woman with the disease was found to be free of the virus when examined for amniotic fluid, umbilical cord, placenta, and breast milk after delivery.

Clinical course of coronavirus infection during pregnancy is characterized by a slow development of symptoms (hyperactivity) or rapid transition to severe degree. Perhaps, for this reason, it is possible to go with increased body temperature, massive bleeding and acute respiratory failure, with the addition of septic processes, mainly during childbirth or after childbirth, to compensate for clinical symptoms in pregnant women affected by coronavirus up to now.

Dangerous groups in which severe course of the disease is observed include: pregnant women, women with especially in the third decade, postpartum women, children and adults (less than two years and older than 65 years), overweight patients and patients with chronic diseases (lung disease, bronchial asthma, chronic bronchitis, cardiovascular disease, diabetes diabetes, etc.).

The tactics of etiotropic treatment of women who have an infection of COVID-19 during pregnancy and lactation have not yet been developed. The drug Ribavirin and recombinant interferon beta-1b can not be used during pregnancy. However, as an etiotropic therapy, antiviral drugs can be prescribed taking into account the effectiveness of the drug against the new coronavirus, taking into account the vital indications. In other cases, their safety should be taken into account during pregnancy and during breastfeeding. Prescribe Lopinavir + ritonavir is possible if the expected benefit for the mother is greater than the potential risk for the fetus: 400 mg lopinavir + 100 mg ritonavir is prescribed in the form of tablets every 12 hours for 14 days. If oral administration is not possible, the drugs (400 mg lopinavir+100 mg ritonavir) are injected through the nasogastric tube in the form of a suspension every 12 hours (5 ml) for 14 days.

Treatment should be started as early as possible, which will ensure a faster recovery. For pregnant women with a severe or progressive type of disease, antiviral drugs should be prescribed, even if they have passed much earlier than the day the disease began. When prescribing antiviral drugs to nursing mothers, the decision to continue breastfeeding depends on the condition of the mother. Pathogenetic and symptomatic treatment. The first choice is antipyretic drug paracetamol, which is prescribed 500 - 1000 mg 4 times a day (no more than 4 g per day).

For pregnant women: who recommends antenatal corticosteroid therapy. This is because there is a risk of premature pregnancy from 24 weeks to 34 weeks.

But if the mother does not have any signs of infection, it is recommended during childbirth and as a support for a newborn.

In addition, if symptoms of a mild degree of COVID-19 infection are observed in women, when the clinical advantage of corticosteroid for the fetus is higher than the danger for the mother. In this case, it is necessary to talk in detail about the benefit and harm between the fetus and the infantile baby with the pregnant woman, and to come to a clear conclusion, taking into account the desire to please the woman and her family, as well as the availability of health resources.

Obstetric tactics in several aspects: the patient's condition, the state of the fetus and the period of pregnancy. Up to 12 weeks in severe and moderate-weight diseases depends. Pregnancy with a high risk of prenatal complications, it is recommended to stop pregnancy after the treatment of infectious jaundice. If the patient refuses to stop pregnancy, a biopsy of chorionic fibers is necessary to identify chromosomal abnormalities in the fetus.

The period of exacerbation of the disease can be attributed to the death of mothers and numerous complications: aggravation of the underlying disease and its complications, the development of respiratory failure, the appearance of obstetric bleeding, postpartum death, and purulent-septic complications after childbirth.

However, if it is not possible to eliminate hypoxia in progressive respiratory failure using pulmonary artificial ventilation, early delivery by cesarean section with all necessary precautions in case of refractory septic shock for the benefit of the mother with alveolar lung tumor and vital signs will be. It is preferable to give birth in the natural way, under the monitoring of the condition of the mother and fetus, if there is a development of spontaneous complications, when the disease is in the outbreaks and the risk of pneumonia is high.

This should include complete analgesia, detoxification, antibacterial and antiviral therapy, and respiratory support.

In the second period, it is necessary to limit the tension of the pregnant woman to prevent respiratory and cardiovascular failure. If it is necessary to accelerate labor,

there will be instructions to remove the fetus by vacuum-extraction by placing two obstetric clamps. Cesarean section is performed if there is an absolute obstetric indication and the pregnant woman dies (to save the fetal life). In severe cases, regional methods of anesthesia in the background of respiratory support in the absence of signs of polyorgan failure (up to 2 points on the SOFA scale) are used in the provision of anesthetic care for caesarean section, total intravenous anesthesia using artificial lung ventilation when signs of polyorgan deficiency are evident.

All patients undergo bleeding profilactics regardless of the time of pregnancy. In all cases, the issue of time and method of delivery is decided individually.

Literature list

1. Dustova N.K., Babadjanova G.S., Ikhtiyarova G.A. Pathogenetic reasons for the development of varicose discounts in pregnant women .Centralodiasian.No.2 (2) P 87-96
2. Gagnier J.J., Kienley G., Altman D.G., Moher D., Sox H., Riley D., et al. CARE Recommendations: Developing guidelines for case management based on consensus. *GlobAdvHealthMed.* 2013; 2: 38–43.
3. Ikhtiyarova G.A., Dustova N.K., Babadjanova G.S. Pathogenetic reasons for the development of varicose disease in pregnant women // *Central Asian journal of pediatrics.* -2019.No.2 (2). - С.78-85
4. Ikhtiyarova G. et al. Criteria For Prediction Of Complications In Pregnant Women With Antenatal Fetal Death // *International Journal of Research.* – 2019. – Т. 6. – №. 01. – P. 694-704.
5. Ikhtiyarova G.A., Dustova N.K., Qayumova G. Diagnostic characteristics of pregnancy in women with antenatal fetal death// *European Journal of Research.* - 2017. - №5(5). - P. 3 - 15.
6. Ikhtiyarova, G. A., Dustova, N. K., Khasanova M. A., Suleymanova G. S., & Davlatov, S. S. (2021). Pathomorphological changes of the placenta in pregnant women infected with coronavirus COVID-19. *International Journal of Pharmaceutical Research*, 13(1), 1935-1942. doi: 10.31838/ijpr/2021.13.01.283
7. Ikhtiyarova, G.A., Tosheva, I.I., Aslonova, M.J., Dustova, N.K. Prenatal rupture of amnion membranes as A risk of development of obstetrics pathologies // *European Journal of Molecular and Clinical Medicine*, 2020, 7(7), стр. 530–535
8. Inoyatov A.Sh., Ikhtiyarova G.A., Musaeva D.M., Karimova G.K. Assessment of the status of pregnant women with diabetes mellitus infected with COVID-19 // *New day in medicine*, 2020, 2(30), P - 102
9. ИХТИЯРОВА Г. А., ДУСТОВА Н. К., КУДРАТОВА Р. Р., БАХРАМОВА С. У. И ХАФИЗОВА Д. Б. (2021). Предкурсовая подготовка женщин с репродуктивной потерей плода в анамнезе. *Анналы Румынского общества клеточной биологии*, 6219-6226.
10. Бахадуровна, Х. Д., и Акмаловна, И. Г. (2022). РОЛЬ МУЛЬТИГЕННОЙ ТРОМБОФИЛИИ У ЖЕНЩИН С НЕБЛАГОПРИЯТНЫМИ ИСХОДАМИ ПОСЛЕ ЭКСТРАКОРПОРАЛЬНОГО ОПЛОДОТВОРЕНИЯ. *Журнал анализа и изобретений ResearchJet*, 3(1), 44-50.
11. Хафизова, Д. Б. (2023). Оценка Роли Генетического Полиморфизма Факторов Системы Гемостаза Гена F3 в Развитии Тромбофилии у Женщин Узбекской Популяции. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(11), 225-234.
12. Khafizova, D. B. (2023). Assessment of the Role of Genetic Polymorphism of the Hemostatic System Factors of the F3 Gene in the Development of Thrombophilia in Women of the Uzbek Population. *Central Asian Journal of Medical and Natural Science*, 4(6), 659-667.

13. Хафизова, Д. Б. (2023). Роль Полиморфизма G/A Гена F7 Фактора В Генезе Неблагополучных ЭКО. *AMALIY VA TIBBIYOT FANLARI ILMIIY JURNALI*, 2(12), 127-133.
14. Хафизова, Д. Б. (2023). ОЦЕНКА ЗНАЧИМОСТИ G/A ПОЛИМОРФИЗМА ГЕНА THEF7 В РАЗВИТИИ НЕБЛАГОПРИЯТНОГО ИСХОДА ЭКО У ЖЕНЩИН С ТРОМБОФИЛИЕЙ. *Британский медицинский журнал*, 3(2).
15. Хафизова, Д. Б., & Ихтиярова, Г. А. (2022). Оценка Роли Генетического Полиморфизма Факторов Системы Гемостаза Гена F3 В Развитии Тромбофилии У Женщин Узбекской Популяции. *AMALIY VA TIBBIYOT FANLARI ILMIIY JURNALI*, 1(5), 20-28.
16. Аслонова, М. Ж., Ихтиярова, Г. А., Хафизова, Д. Б., & Мирзоева, М. Р. (2018). МИКРОБИОЛОГИЧЕСКАЯ И ГОРМОНАЛЬНАЯ ХАРАКТЕРИСТИКА ФОРМИРОВАНИЯ НЕРАЗВИВАЮЩЕЙСЯ БЕРЕМЕННОСТИ. In *ФУНДАМЕНТАЛЬНЫЕ И ПРАКТИЧЕСКИЕ ВОПРОСЫ ИММУНОЛОГИИ И ИНФЕКТОЛОГИИ* (pp. 9-15).
17. Ихтиярова, Г. А., Курбанова, З. Ш., & Хафизова, Д. Б. ВОСПАЛИТЕЛЬНЫЕ ИЗМЕНЕНИЯ В СИСТЕМЕ МАТЬ-ПЛАЦЕНТА-ПЛОД ПРИ АНТЕНАТАЛЬНОЙ ГИБЕЛИ ПЛОДА.
18. Dustova N.K. Hypertension and pregnancy // *News of Dermatovenereology and Reproductive Health*. 2014.Vol.2. P. 86.
19. Dustova N.K. Features of the course of pregnancy and its outcome depending on the severity of preeclampsia // *Problems of Biology and Medicine*, 2012.Vol. 1.P. 129.
20. Ikhtiyarova G.A., Khaibullina Z.R., Suleimanova G.G. Study of the effects of ultra-low doses of antioxidants on the lipid component of brain cells in experimental perinatal hypoxia // *News of Dermatovenereology and Reproductive Health*. - 2019. - No. 3 - 4. - С. 4 - 7.
21. Ikhtiyarova G.A., *Dobrokhotova Yu.E., Matrizaeva G.Zh., Aslonova M.Zh.*- Features of a current pregnancy and delivery in pregnant women with varicose // *Tibbiyotda yangi kun*. - 2020. -S. 474-481.
22. Ikhtiyarova G.A., Khodzhaeva N.B., Kosimova N.I.Etiology of varicose veins of the small pelvis during pregnancy // *Problems of Biology and Medicine*. Samarkand. 2012 No. 1 (68) .- P.154-155
23. Kirienko A.I., Bogachev V.Yu., Prokubovsky V.I.Varicose veins of the small pelvis. *Phlebology*. // Ed. V.S. Saveliev. Moscow. Medicine 2015; - S. 246.
24. Mukhiddinovna, I. M. (2022). Effects of chronic consumption of energy drinks on liver and kidney of experimental rats. *International Journal of Philosophical Studies and Social Sciences*, 2(4), 6-11.
25. Mukhiddinovna, I. M. (2022). EFFECTS OF CHRONIC CONSUMPTION OF ENERGY DRINKS ON LIVER AND KIDNEY OF EXPERIMENTAL RATS. *International Journal of Philosophical Studies and Social Sciences*, 2(4), 6-11.
26. Muxiddinovna, I. M. (2022). Impact of energy drinks and their combination with alcohol to the rats metabolism. *Gospodarka i Innowacje.*, 22, 544-549.
27. Muxiddinovna, I. M. (2022). IMPACT OF ENERGY DRINKS AND THEIR COMBINATION WITH ALCOHOL TO THE RATS METOBOLISM. *Gospodarka i Innowacje.*, 22, 544-549.
28. Muxiddinovna, I. M. (2022). Effects of Energy Drinks on Biochemical and Sperm Parameters in Albino Rats. *Central Asian Journal of Medical and Natural Science*, 3(3), 126-131.
29. Muxiddinovna, I. M. (2022). Demage of Energy Drinks on the Spermatogenesis of Male Rat's. *Research Journal of Trauma and Disability Studies*, 1(9), 111-118.
30. Muxiddinovna, I. M. (2022). Effects of Energy Drinks on Biochemical and Sperm Parameters in Albino Rats. *Central Asian Journal of Medical and Natural Science*, 3(3), 126-131.

31. Muxiddinova, I. M. (2022). Impact of energy drinks and their combination with alcohol to the rats metabolism. *Gospodarka i Innowacje.*, 22, 544-549.
32. Muxiddinova, I. M. (2022). Ameliorative effect of Omega-3 on energy drinks-induced pancreatic toxicity in adult male albino rats. *International Journal of Health Systems and Medical Sciences*, 1(5), 13-18.
33. Muxiddinova, I. M., & Sobirova, A. Z. (2022). Pregnancy with Twins with Preeclampsia. *Central Asian Journal of Literature, Philosophy and Culture*, 3(11), 212-221.
34. Muxiddinova, I. M., & Sobirova, A. Z. (2022). Anemia Iron Deficiency in Pregnancy. *Central Asian Journal of Literature, Philosophy and Culture*, 3(11), 191-199.
- 35.
36. Mukhiddinova, I. M. (2022). ENERGY DRINKS MAY AFFECT THE OVARIAN RESERVE AND SERUM ANTI-MULLERIAN HORMONE LEVELS IN A RAT MODEL. *BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI*, 2(12), 626-632.
37. Mukhiddinova, I. M. (2023). High Caffeine Exposure Increases Ovarian Estradiol Production in Immature Rats. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, 2(3), 8-11.
38. Mukhiddinova, I. M. (2023). Energy Fluids May Affect the Ovarian Reserve and Serum Anti-Mullerian Hormone Level. *Scholastic: Journal of Natural and Medical Education*, 2(5), 358-364.
39. Mukhiddinova, I. M. (2022). ENERGY DRINKS MAY AFFECT THE OVARIAN RESERVE AND SERUM ANTI-MULLERIAN HORMONE LEVELS IN A RAT MODEL. *BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI*, 2(12), 626-632.
40. Ismatova, M. M. (2023). Energy Drinks May Affect the Ovary. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(8), 34-38.
41. Suratova, S. S., & Muxiddinova, I. M. (2023). Genetic Polymorphisms in Interleukin-1 β (Rs1143634) and Interleukin-8 (Rs4073) Are Associated With Survival after Resection of Intrahepatic Cholangiocarcinoma. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(8), 39-46.
42. Ismatova, M. M. (2023). Energy Drinks May Affect the Ovary. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(8), 34-38.
43. Mukhiddinova, I. M. (2022). ENERGY DRINKS MAY AFFECT THE OVARIAN RESERVE AND SERUM ANTI-MULLERIAN HORMONE LEVELS IN A RAT MODEL. *BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI*, 2(12), 626-632.
44. Mukhiddinova, I. M. (2023). Energy Fluids May Affect the Ovarian Reserve and Serum Anti-Mullerian Hormone Level. *Scholastic: Journal of Natural and Medical Education*, 2(5), 358-364.
45. Muxiddinova, I. M. (2024). GENETIC POLYMORPHISMS IN INTERLEUKIN-1B (RS1143634) AND INTERLEUKIN-8 (RS4073) ARE ASSOCIATED WITH SURVIVAL AFTER RESECTION OF INTRAHEPATIC CHOLANGIOCARCINOMA. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 101-115.
46. Исмадова, М. М. (2024). ПРОГНОЗИРОВАНИЕ ВЕГЕТАТИВНЫХ НАРУШЕНИЙ У БЕРЕМЕННЫХ ПЕРЕНЕСШИХ COVID-19. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 161-174.
47. Исмадова, М. М. (2024). ПРОГНОЗИРОВАНИЕ ДЕПРЕССИВНЫХ НАРУШЕНИЙ У БЕРЕМЕННЫХ И РОДИЛЬНИЦ ПОСЛЕ КОРОНАВИРУСНОЙ ИНФЕКЦИИ. *Journal of new century innovations*, 46(1), 140-151.
48. Muxiddinova, I. M. (2024). GENETIC POLYMORPHISMS IN INTERLEUKIN-1B (RS1143634) AND INTERLEUKIN-8 (RS4073) ARE ASSOCIATED WITH SURVIVAL AFTER RESECTION OF INTRAHEPATIC CHOLANGIOCARCINOMA. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 101-115.
49. Muxiddinova, I. M. (2024). GENETIC POLYMORPHISMS IN INTERLEUKIN-1B (RS1143634) AND INTERLEUKIN-8 (RS4073) ARE ASSOCIATED WITH SURVIVAL AFTER RESECTION OF

INTRANEPTIC CHOLANGIOCARCINOMA. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 38(6), 101-115.

50. Исмадова, М. М. (2024). ПОСЛЕРОДОВЫХ ОСЛОЖНЕНИЙ. *Journal of new century innovations*, 46(1), 152-159.
51. Исмадова, М. М. (2024). ПОСЛЕРОДОВЫХ ОСЛОЖНЕНИЙ. *Journal of new century innovations*, 46(1), 152-159.
52. Исмадова, М. М. (2024). ВЕГЕТАТИВНЫХ НАРУШЕНИЙ У БЕРЕМЕННЫХ ПЕРЕНЕСШИХ COVID-19. *Journal of new century innovations*, 46(1), 129-132.
53. Ismatova, M. M. (2024). PROBLEMS OF LATE POSTPARTUM COMPLICATIONS AND ITS CORRECTION. *Journal of new century innovations*, 46(1), 160-167.
54. Ихтиярова, Г. А., & Розикова, Д. К. (2023). МИКРОБИОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ У БЕРЕМЕННЫХ С РЕПРОДУКТИВНЫМИ ПОТЕРЯМИ В АНАМНЕЗЕ. *Finland International Scientific Journal of Education, Social Science & Humanities*, 11(4), 1002-1008.
55. Розикова, Д. К., & Ихтиярова, Г. А. (2023). THE STRUCTURE OF REPRODUCTIVE LOSSES IN UZBEK WOMEN. *ЖУРНАЛ РЕПРОДУКТИВНОГО ЗДОРОВЬЯ И УРО-НЕФРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ*, 4(4).
56. Rozikova , D. K. (2023). THE IMPACT OF SUBCHORIONIC HEMATOMA ON THE FINAL RESULT OF PREGNANCIES IN INDIVIDUALS EXPERIENCING THREATENED ABORTION. *GOLDEN BRAIN*, 1(28), 57-62.
57. Rozikova Dildora Kodirovna. (2023). The Pattern of Reproductive Losese among Women in Uzbekistan's Population. *American Journal of Pediatric Medicine and Health Sciences* (2993-2149), 1(8), 52-60.
58. Kodirovna, R. D. (2023). The Effects of Subchorionic Hematoma on Pregnancy Outcome in Patients with Threatened Abortion. *Best Journal of Innovation in Science, Research and Development*, 2(10), 121-124.
59. Ikhtiyarova, G. A., Dustova, N. K., & Qayumova, G. (2017). Diagnostic characteristics of pregnancy in women with antenatal fetal death. *European Journal of Research*, (5), 5.
60. Kayumova, G. M., & Nutfilloyevich, K. K. (2023). CAUSE OF PERINATAL LOSS WITH PREMATURE RUPTURE OF AMNIOTIC FLUID IN WOMEN WITH ANEMIA. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(11), 131-136.
61. Kayumova, G. M., & Dustova, N. K. (2023). Significance of the femoflor test in assessing the state of vaginal microbiocenosis in preterm vaginal discharge. *Problems and scientific solutions. In International conference: problems and scientific solutions. Abstracts of viii international scientific and practical conference* (Vol. 2, No. 2, pp. 150-153).
62. Каюмова, Г. М., Мухторова, Ю. М., & Хамроев, Х. Н. (2022). Определить особенности течения беременности и родов при дородовом излитии околоплодных вод. *Scientific and innovative therapy. Научный журнал по научный и инновационный терапии*, 58-59.
63. Kayumova, G. M., & Dustova, N. K. (2023). ASSESSMENT OF THE STATE OF THE GENITAL TRACT MICROBIOCENOSIS IN PREGNANT WOMEN WITH PREMATURE RUPTURE OF THE MEMBRANES USING THE FEMOFLOL TEST. *Modern Scientific Research International Scientific Journal*, 1(1), 70-72.
64. Valeryevna, S. L., Mukhtorovna, K. G., & Kobylovna, E. S. (2019). Premature Birth In A Modern Aspect. *International Journal of Bio-Science and Bio-Technology*, 11(10), 31-37.

65. Саркисова, Л. В., Каюмова, Г. М., & Умидова, Н. Н. (2018). Морфологические изменения фетоплацентарного комплекса при герпетической инфекции. *Тиббиётда янги кун*, 188-191.
66. Каюмова, Г. М., Саркисова, Л. В., & Умидова, Н. Н. (2018). Современные взгляды на проблему преждевременных родов. *Тиббиётда янги кун*, 183-185.
67. Каюмова, Г. М., Хамроев, Х. Н., & Ихтиярова, Г. А. (2021). *Причины риска развития преждевременных родов в период пандемии организм и среда жизни к 207-летию со дня рождения Карла Францевича Рулье: сборник материалов IV-ой Международной научно-практической конференции (Кемерово, 26 февраля 2021 г.)*. ISBN 978-5-8151-0158-6.139-148.
68. Саркисова, Л. В., Каюмова, Г. М., & Бафаева, Н. Т. (2019). Причины преждевременных родов и пути их решения. *Биология ва тиббиёт муаммолари*, 115(4), 2.
69. Kayumova, G. M., & Dustova, N. K. (2023). Significance of the femoflor test in assessing the state of vaginal microbiocenosis in preterm vaginal discharge. Problems and scientific solutions. In *International conference: problems and scientific solutions. Abstracts of viii international scientific and practical conference* (Vol. 2, No. 2, pp. 150-153).
70. KAYUMOVA, G., & DUSTOVA, N. (2023). *Features of the hormonal background with premature surge of amniotic fluid. Of the international scientific and practical conference of young scientists «Science and youth: conference on the quality of medical care and health literacy» Ministry of healthcare of the republic of kazakhstan kazakhstan's medical university «KSPH»*. ISBN 978-601-305-519-0.29-30.
71. Каюмова, Г. М. НҚ Дўстова.(2023). Muddatdan oldin qog'onoq suvining ketishida xavf omillarning ta'sirini baholash. *Журнал гуманитарных и естественных наук*, 2(07), 11-18.
72. Каюмова, Г. М., & Мухторова, Ю. М. (2022). Пороговые значения антител к эстрадиолу, прогестерону и бензо [а] пирену как факторы риска преждевременного излития околоплодных вод при недоношенной беременности. *Scientific and innovative therapy. Научный журнал по научный и инновационный терапии*, 59-60.
73. Каюмова, Г. М., Мухторова, Ю. М., & Хамроев, Х. Н. (2022). Причина преждевременных родов. *Scientific and innovative therapy. Научный журнал по научный и инновационный терапии*, 57-58.
74. Sarkisova, L. V., & Kayumova, G. M. (2019). Exodus of premature birth. *Тиббиётда янги кун*, 1(25), 155-159.
75. Саркисова, Л. В., & Каюмова, Г. М. (2018). Перинатальный риск и исход преждевременных родов. *Проблемы медицины и биологии*, 169-175.
76. Каюмова, Г. М., Саркисова, Л. В., & Рахматуллаева, М. М. (2018). Особенности состояния плаценты при преждевременных родах. In *Республиканской научно практической конференции «Актуальные вопросы охраны здоровья матери и ребенка, достижения и перспективы* (pp. 57-59).
77. Каюмова, Г. М., Саркисова, Л. В., & Саьдуллаева, Л. Э. (2018). Показатели центральной гемодинамики и маточно-фетоплацентарного кровотока при недонашивании беременности. In *Республиканской научно практической конференции «Актуальные вопросы охраны здоровья матери и ребенка, достижения и перспективы* (pp. 56-57).
78. Саркисова, Л., Каюмова, Г., & Рузиева, Д. (2019). Современные тренды преждевременных родов. *Журнал вестник врача*, 1(4), 110-114.
79. Каюмова, Г. М., & Ихтиярова, Г. А. (2021). Причина перинатальных потер при преждевременных родов у женщин с анемией.(2021). In *Материалы республиканской научно-практической онлайн конференции.«Актуальные проблемы современной медицины в условиях эпидемии* (pp. 76-7).
80. Kayumova, G. M., Khamroev, X. N., & Ixtiyarova, G. A. (2021). Morphological features of placental changes in preterm labor. *Тиббиётда янги кун*, 3(35/1), 104-107.
81. Khamroyev XN, Q. G. (2021). Improving the results of treatment of choledocholithiasis in liver diseases.

82. Kayumova, G. M. (2023). TO DETERMINE THE FEATURES OF THE COURSE OF PREGNANCY AND CHILDBIRTH IN WOMEN WITH PRENATAL RUPTURE OF AMNIOTIC FLUID. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(11), 137-144.
83. Kayumova, G. M. (2023). To Determine the Features Of Pregnancy and Children During Antenature Ruption Of Ambient Fluid. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(9), 66-72.
84. Kayumova, G. M. (2023). Features of the Hormonal Background During Premature Relation of Ambitional Fluid. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(9), 73-79.
85. Kayumova, G. M. (2023). The Significance Of Anti-Esterogen And Progesterone Antibodies As A Risk Factor In Premature Rupture Of Amniotic Fluid. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(9), 58-65.
86. Каюмова, Г. М. (2024). ПЕРИНАТАЛЬНЫЕ ИСХОДЫ ПРИ ДОРОДОВОМ РАЗРЫВЕ ПЛОДНЫХ ОБОЛОЧЕК. *Journal of new century innovations*, 46(1), 242-251.
87. Каюмова, Г. М. (2024). ОПРЕДЕЛИТЬ ФАКТОРЫ РИСКА ПРЕЖДЕВРЕМЕННЫХ РОДОВ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 228-235.
88. Каюмова, Г. М. (2024). ОСОБЕННОСТИ КАЧЕСТВЕННОГО СОСТАВА МИКРОБИОТА ВЛАГАЛИЩА ПРИ АКТИВНО-ВЫЖИДАТЕЛЬНОЙ ТАКТИКЕ ВЕДЕНИЯ БЕРЕМЕННЫХ С ПРЕЖДЕВРЕМЕННЫМ ИЗЛИТИЕМ ОКОЛОПЛОДНЫХ ВОД. *Journal of new century innovations*, 46(1), 231-241.
89. Каюмова, Г. М. (2024). ИССЛЕДОВАНИЕ МИКРОБИОТА ВЛАГАЛИЩА ПРИ ДОРОДОВОМ ИЗЛИТИИ ОКОЛОПЛОДНЫХ ВОД. *Journal of new century innovations*, 46(1), 213-221.
90. Каюмова, Г. М. (2024). ИССЛЕДОВАНИЕ ПОКАЗАТЕЛЕЙ КРОВИ У БЕРЕМЕННЫХ С ПРЕЖДЕВРЕМЕННЫМИ ОКОЛОПЛОДНЫМИ ВОДАМИ. *Journal of new century innovations*, 46(1), 222-230.
91. Kayumova, G. M. (2024). ANTIBACTERIAL THERAPY FOR PRETERMARY AND ANTENATURE RURUSION OF AMBITIONAL FLUID. *Journal of new century innovations*, 46(1), 252-262.
92. Уроков, Ш. Т., & Хамроев, Х. Н. (2019). Influe of diffusion diseases of the liver on the current and forecfst of obstructive jaundice. *Тиббиётда янги кун*, 1, 30.
93. TESHAEV, S. J., TUHSANOVA, N. E., & HAMRAEV, K. N. (2020). Influence of environmental factors on the morphometric parameters of the small intestine of rats in postnatal ontogenesis. *International Journal of Pharmaceutical Research (09752366)*, 12(3).
94. Хамроев, Х. Н. (2022). Toxic liver damage in acute phase of ethanol intoxication and its experimental correction with chelate zinc compound. *European journal of modern medicine and practice*, 2, 2.
95. Khamroev, B. S. (2022). RESULTS OF TREATMENT OF PATIENTS WITH BLEEDING OF THE STOMACH AND 12 DUO FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS-INDUCED OENP. *Journal of Pharmaceutical Negative Results*, 1901-1910.
96. Nutfilloyevich, K. K. (2023). STUDY OF NORMAL MORPHOMETRIC PARAMETERS OF THE LIVER. *American Journal of Pediatric Medicine and Health Sciences (2993-2149)*, 1(8), 302-305.
97. Nutfilloyevich, K. K. (2024). NORMAL MORPHOMETRIC PARAMETERS OF THE LIVER OF LABORATORY RATS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(3), 104-113.
98. Nutfilloevich, K. K., & Akhrorovna, K. D. (2024). MORPHOLOGICAL CHANGES IN THE LIVER IN NORMAL AND CHRONIC ALCOHOL POISONING. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(3), 77-85.
99. Kayumova, G. M., & Hamroyev, X. N. (2023). SIGNIFICANCE OF THE FEMOFLOR TEST IN ASSESSING THE STATE OF VAGINAL MICROBIOCENOSIS IN PRETERM VAGINAL DISCHARGE. *International Journal of Medical Sciences And Clinical Research*, 3(02), 58-63.

100. Хамроев, Х. Н., & Тухсанова, Н. Э. (2022). **НОВЫЙ ДЕНЬ В МЕДИЦИНЕ. НОВЫЙ ДЕНЬ В МЕДИЦИНЕ Учредители: Бухарский государственный медицинский институт, ООО "Новый день в медицине"**, (1), 233-239.
101. Хамроев, Х. Н. (2024). Провести оценку морфологических изменений печени в норме и особенностей характера ее изменений при хронической алкогольной интоксикации. **ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ**, 36(3), 95-3.
102. Хамроев, Х. Н., & Тухсанова, Н. Э. (2021). Characteristic of morphometric parameters of internal organs in experimental chronic alcoholism. *Тиббийётда янги кун*, 2, 34.
103. Хамроев, Х. Н., Хасанова, Д. А., Ганжиев, Ф. Х., & Мусоев, Т. Я. (2023). Шошилич тиббий ёрдам ташкил қилишнинг долзарб муаммолари: Политравма ва ўткир юрак-қон томир касалликларига ёрдам кўрсатиш масалалари. *XVIII Республика илмий-амалий анжумани*, 12.
104. Хамроев, Х. Н., & Хасанова, Д. А. (2023). Жигар морфометрик кўрсаткичларининг меъёра ва экспериментал сурункали алкоголизмда қиёсий таснифи. *Медицинский журнал Узбекистана | Medical journal of Uzbekistan*, 2.
105. Khamroyev, X. N. (2022). TOXIC LIVER DAMAGE IN ACUTE PHASE OF ETHANOL INTOXICATION AND ITS EXPERIMENTAL CORRECTION WITH CHELATE ZINC COMPOUND. *European Journal of Modern Medicine and Practice*, 2(2), 12-16.
106. Khamroyev, X. N. (2022). The morphofunctional changes in internal organs during alcohol intoxication. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 2(2), 9-11.
107. Khamroyev, X. N. (2022). TOXIC LIVER DAMAGE IN ACUTE PHASE OF ETHANOL INTOXICATION AND ITS EXPERIMENTAL CORRECTION WITH CHELATE ZINC COMPOUND. *European Journal of Modern Medicine and Practice*, 2(2), 12-16.
108. Khamroyev, X. N. (2022). The morphofunctional changes in internal organs during alcohol intoxication. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 2(2), 9-11.
109. Латипов, И. И., & Хамроев, Х. Н. (2023). Улучшение Результат Диагностики Ультразвуковой Допплерографии Синдрома Хронической Абдоминальной Ишемии. *Central Asian Journal of Medical and Natural Science*, 4(4), 522-525.
110. Хамроев, Х. Н., & Уроков, Ш. Т. (2019). ВЛИЯНИЕ ДИФФУЗНЫХ ЗАБОЛЕВАНИЙ ПЕЧЕНИ НА ТЕЧЕНИЕ И ПРОГНОЗ МЕХАНИЧЕСКОЙ ЖЕЛТУХИ. *Новый день в медицине*, (3), 275-278.
111. Хамроев, Х. Н., & Ганжиев, Ф. Х. (2023). Динамика структурно-функциональных нарушение печени крыс при экспериментальном алкоголине циррозе. *Problems of modern surgery*, 6.
112. Уроков, Ш. Т., & Хамроев, Х. Н. (2018). Клинико-диагностические аспекты механической желтухи, сочетающейся с хроническими диффузными заболеваниями печени (обзор литературы). *Достижения науки и образования*, (12 (34)), 56-64.
113. Nutfilloevich, N. K., & Akhrorovna, K. D. (2023). COMPARATIVE CLASSIFICATION OF LIVER MORPHOMETRIC PARAMETERS IN THE LIVER AND IN EXPERIMENTAL CHRONIC ALCOHOLISM. *International Journal of Cognitive Neuroscience and Psychology*, 1(1), 23-29.